Eilean Therapeutics Acquires Ness Therapeutics

Eilean Therapeutics Acquires Ness Therapeutics

By, Admin 7 March 2024

Eilean Therapeutics acquires best-in-class PTPN2 provider Ness Therapeutics

Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction. Ness is developing best-in-class PTPN2 inhibitors providing an immuno-oncological therapy with an improved safety and tolerability profile.

About PTPN2

  • Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is ubiquitously expressed, primarily in hematopoietic and placental cells. 
  • As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signalling through cytokine receptors, including IFN?. Thus, enhancing IFN? sensing and signalling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.

Active Lead Molecule

Ness' lead molecules demonstrate sub-nanomolar PTPN2/PTPN1 inhibitory activity and outstanding > 1000-fold selectivity against all other phosphatases, exhibit high oral bioavailability and good safety. In addition, lead inhibitors induce tumor cells' susceptibility to IFN? and suppress their growth with a high efficacy.

About Eilean Therapeutics

  • Eilean Therapeutics LLC is a biopharmaceutical company co-founded by Orbimed, Torrey Pines Investment and Dr John C. Byrd, focused on the discovery and development of best-in-class and first-in-class small molecule inhibitors that target resistance mechanisms in hematologic and solid cancers. 
  • The company is utilizing a proprietary hybrid AI platform of Expert Systems accelerator, leveraging its key partners' proprietary data, chem and bio tools, knowledge and expertise to choose highly valuable molecular mechanism of pathology, to rationally design, accelerate discovery and optimize development of best-in-class and first-in-class therapies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!